High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI.
7 Tesla
Concentric circle trajectories
Glycine
High-grade glioma
Magnetic resonance spectroscopic imaging
Metabolic imaging
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
05
2020
revised:
08
09
2020
accepted:
09
09
2020
pubmed:
26
9
2020
medline:
29
6
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
Successful neurosurgical intervention in gliomas depends on the precision of the preoperative definition of the tumor and its margins since a safe maximum resection translates into a better patient outcome. Metabolic high-resolution imaging might result in improved presurgical tumor characterization, and thus optimized glioma resection. To this end, we validated the performance of a fast high-resolution whole-brain 3D-magnetic resonance spectroscopic imaging (MRSI) method at 7T in a patient cohort of 23 high-grade gliomas (HGG). We preoperatively measured 23 patients with histologically verified HGGs (17 male, 8 female, age 53 ± 15) with an MRSI sequence based on concentric ring trajectories with a 64 × 64 × 39 measurement matrix, and a 3.4 × 3.4 × 3.4 mm Eighteen of the patient measurements were considered usable. In these patients, ten metabolites were quantified with acceptable quality. Gln, Gly, and tCho were increased and NAA and tCr decreased in nearly all tumor regions, with other metabolites such as serine, showing mixed trends. Overall, there was a reliable characterization of metabolic tumor areas. We also found heterogeneity in the metabolic images often continued into the peritumoral region. While 2HG could not be satisfyingly quantified, we found an increase of Glu in the contrast-enhancing region of IDH-wildtype HGGs and a decrease of Glu in IDH1-mutant HGGs. We successfully demonstrated high-resolution 7T 3D-MRSI in HGG patients, showing metabolic differences between tumor regions and peritumoral tissue for multiple metabolites. Increases of tCho, Gln (related to tumor metabolism), Gly (related to tumor proliferation), as well as decreases in NAA, tCr, and others, corresponded very well to clinical tumor segmentation, but were more heterogeneous and often extended into the peritumoral region.
Identifiants
pubmed: 32977210
pii: S2213-1582(20)30270-9
doi: 10.1016/j.nicl.2020.102433
pmc: PMC7511769
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102433Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 646
Pays : Austria
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Sci Rep. 2016 May 18;6:25919
pubmed: 27189490
Antioxidants (Basel). 2017 Aug 03;6(3):
pubmed: 28771170
Magn Reson Med. 2017 Aug;78(2):429-440
pubmed: 27548836
Clin Neurol Neurosurg. 2013 Feb;115(2):146-53
pubmed: 23237636
Magn Reson Med. 2018 Mar;79(3):1231-1240
pubmed: 28643447
Eur Radiol. 2016 Aug;26(8):2670-84
pubmed: 26471274
Cancers (Basel). 2020 Jan 29;12(2):
pubmed: 32013066
Med Phys. 2018 Jan;45(1):328-339
pubmed: 29106741
Neurosurg Focus. 2015 Jan;38(1):E4
pubmed: 25552284
NMR Biomed. 2020 May 12;:e4314
pubmed: 32399974
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
Invest Radiol. 2017 Oct;52(10):631-639
pubmed: 28459799
Radiology. 2014 Aug;272(2):494-503
pubmed: 24661247
Radiology. 2017 Jul;284(1):180-190
pubmed: 28240563
Neuroimage. 2015 Nov 1;121:126-35
pubmed: 26210813
NMR Biomed. 2019 Aug;32(8):e4109
pubmed: 31131943
Magn Reson Med. 2009 Oct;62(4):1042-6
pubmed: 19526507
NMR Biomed. 2020 Apr 29;:e4309
pubmed: 32350978
Magn Reson Med. 2019 Nov;82(5):1587-1603
pubmed: 31183893
J Cell Biol. 2016 Aug 1;214(3):249-57
pubmed: 27458133
NMR Biomed. 2009 Aug;22(7):683-96
pubmed: 19259944
J Magn Reson B. 1994 May;104(1):1-10
pubmed: 8025810
Nature. 2019 Sep;573(7775):532-538
pubmed: 31534219
Magn Reson Med. 2018 Jun;79(6):2874-2885
pubmed: 29106742
Magn Reson Med. 2016 Jan;75(1):52-62
pubmed: 25651788
J Magn Reson Imaging. 2015 May;41(5):1332-41
pubmed: 24935758
J Magn Reson Imaging. 2014 Jul;40(1):181-91
pubmed: 24395184
Magn Reson Med. 2009 Mar;61(3):548-59
pubmed: 19111009
Nature. 2015 Apr 16;520(7547):363-7
pubmed: 25855294
Neuroimage. 2018 Mar;168:199-210
pubmed: 27825954
Neuro Oncol. 2018 Oct 9;20(11):1536-1546
pubmed: 29718366
NMR Biomed. 2013 Dec;26(12):1796-805
pubmed: 24038331
Neuroimage. 2019 May 1;191:587-595
pubmed: 30772399
Int J Oncol. 2010 Feb;36(2):301-6
pubmed: 20043062
J Clin Invest. 2015 Apr;125(4):1591-602
pubmed: 25798620
NMR Biomed. 2011 Jul;24(6):592-611
pubmed: 21538631
Metabolites. 2015 Sep 15;5(3):502-20
pubmed: 26389964
Magn Reson Med. 2019 Aug;82(2):527-550
pubmed: 30919510
Nat Commun. 2018 Apr 16;9(1):1474
pubmed: 29662077
Invest Radiol. 2020 Apr;55(4):239-248
pubmed: 31855587
NMR Biomed. 2012 Jun;25(6):873-82
pubmed: 22190245
AJNR Am J Neuroradiol. 2014 Jun;35(6 Suppl):S31-6
pubmed: 24481330
NMR Biomed. 2012 May;25(5):695-716
pubmed: 22102481
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Radiology. 2009 Dec;253(3):805-12
pubmed: 19789222
NMR Biomed. 2020 Jun 28;:e4350
pubmed: 32596978
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19611-6
pubmed: 22106302
NMR Biomed. 2018 Mar;31(3):
pubmed: 29315915
Magn Reson Med. 2020 Jan;83(1):12-21
pubmed: 31393037
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Magn Reson. 2000 Mar;143(1):95-100
pubmed: 10698650
Magn Reson Med. 2019 Oct;82(4):1259-1265
pubmed: 31131476
Invest Radiol. 2007 Apr;42(4):218-23
pubmed: 17351427